Intersect ENT's sinus implant

Intersect's new sinusitis implant is like its Propel, above, but designed to be implanted without surgery.--Courtesy of Intersect ENT

Company: Intersect ENT
Device: Nonsurgical sinus implant
Drug delivered: mometasone furoate steroid

Why it's important: Intersect ENT's sinus implants continue to make waves in the delivery device industry, the company having recently gained $30 million in Series D funding for its ongoing line of implants. The newest device in Intersect's arsenal, and one to watch despite its recent entry into clinical trials, can be implanted during a normal physician's office visit without surgery, an innovation that could potentially widen the market considerably. The other two implants, Propel and the Propel mini, must be placed by a surgeon, but have already been on the market since 2011.

To treat chronic sinusitis, Intersect ENT's implants release a steroid drug, mometasone furoate, which helps maintain the sinus opening for up to 30 days.

Intersect ENT has gained a ton of interest from financial players, and Medtronic ($MDT) has been one of the major investors in the quarter-sized implants as Intersect pushes for further commercial expansion.

For more:
Intersect ENT pulls in $30M Series D for sinusitis-implant sales push
Intersect ENT sees positive data on Propel from pivotal trial
Intersect ENT CEO discusses Propel implant
Intersect raises $30M for sinus treatment

Intersect ENT's sinus implant
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.